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Introduction: Combining the angiotensin receptor blocker (ARB) Valsartan (VAL) with a neprolysin inhibitor (NEPi) to augment natriuretic peptide 
activity has recently been shown to lower blood pressure in hypertensive patients more potently than VAL alone. We studied the effects of combined 
ARB and NEPi on cardiac fibrosis and hypertrophy.
Methods: Neonatal rat cardiac fibroblasts (NCF) and myocytes (NCM) were stimulated with 100 nmol of angiotensin II (AngII) and co-cultured 
with increasing doses of VAL, the NEPi pro-drug AHU-377 (AHU), its active metabolite, LBQ-657 (LBQ); all alone and in combination. 3[H]proline-
incorporation and 3[H]leucine-incorporation were used to assess collagen production and myocyte hypertrophy, respectively.
Results: AHU had no effects in either cell type (not shown). Addition of 10μM LBQ enhanced the inhibitory effects of Val at each dose compared to 
VAL alone, in particular in NCF, allowing for complete inhibition of AngII-mediated effects at the highest combined VAL+LBQ dose (Table).
Conclusions: We demonstrate that combination of NEPi with ARB further augments the anti-fibrotic and anti-hypertrophic effects afforded by ARB 
alone. These novel findings may explain recent favourable clinical findings and support further clinical study.
Table 
NCM stimulated with 100 nM AngII NCF stimulated with 100nM AngII
VAL dose (μM) 0.0 0.03 0.1 0.3 1.0 0.0 0.03 0.1 0.3 1.0
VAL alone 128 ± 2*** 111 ± 3##
111 ± 
4###
110 ± 
4###
107 ± 
4###
226 ± 9*** 174 ± 9##
144 ± 
7###
124 ± 
5###
112 ± 
4###
VAL+10μM LBQ 109 ± 2###
111 ± 
2###
103 ± 
3###
107 ± 
4###
111 ± 
3###
201 ± 13
136 ± 
13###
122 ± 
6###
107 ± 
8###
104 ± 
3###
Data displayed as % of unstimulated control (=100%)
***p<0.001 vs unstimulated control, #p<0.05, ##p<0.01, ###p<0.001 vs stimulated control.
